Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iovance Biotherapeutics ( (IOVA) ) has provided an update.
On February 24, 2026, Iovance Biotherapeutics reported that 2025 was its first full calendar year of Amtagvi launch, delivering about 30% sequential fourth-quarter revenue growth to roughly $87 million and full-year product revenue of about $264 million, in line with guidance. Gross margin improved to about 50%, the company ended 2025 with about $303 million in cash expected to fund operations into the third quarter of 2027, and operational initiatives such as fully internalizing lifileucel manufacturing are aimed at further lowering costs and supporting a path toward profitability.
In 2025, U.S. Amtagvi sales reached about $220 million and Proleukin about $44 million, supported by a growing network of authorized treatment centers, faster 32-day-or-less manufacturing turnaround, and real-world and trial data showing unprecedented response rates and durable benefit in advanced melanoma. The company advanced its pipeline with U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer, positive interim NSCLC data suggesting a best-in-class profile versus docetaxel, plans for a potential U.S. accelerated approval in 2027, and progress across multiple trials and new indications including sarcomas, frontline melanoma combinations, and next-generation engineered TIL therapies, reinforcing its positioning as a leader in TIL-based cancer treatment.
The most recent analyst rating on (IOVA) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
The score is held back primarily by weak financial performance (large losses and negative cash flows). This is partially offset by constructive technical trends and a relatively upbeat earnings outlook featuring revenue growth, reiterated guidance, and margin-improvement initiatives; valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a commercial biotechnology company specializing in novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer. Its primary products include Amtagvi, a first-in-class TIL therapy for advanced melanoma, and Proleukin, with a growing U.S. and global market focus across solid tumors including melanoma and non-small cell lung cancer.
Average Trading Volume: 11,121,937
Technical Sentiment Signal: Sell
Current Market Cap: $1.08B
See more data about IOVA stock on TipRanks’ Stock Analysis page.